Xenin-8 acetate
Xenin-8 acetate is the C-terminal octapeptide fragment of xenin, which belongs to the xenopsin family of peptides. Xenin-8 acetate stimulates basal insulin secretion, dose-dependently enhances glucose (EC50 = 0.16 nM) and arginine-induced insulin release, and enhances arginine- and Carbamoylcholine chloride (HY-B1208)-induced glucagon secretion. Xenin-8 acetate antagonizes the inhibition of glucagon release by elevated glucose. Xenin-8 acetate can be used in research on type 2 diabetes and obesity-related glucose metabolic disorders.
For research use only. We do not sell to patients.
- Formula: C51H79N15O9·xC2H4O2
- Molecular Weight:1046.27 (free base)
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Xenin-8 (0.1-100 nM; 60 min) acetate dose-dependently enhances glucose-induced insulin release (EC50 = 0.16 nM), enhances arginine-induced insulin release (by 40%), and enhances glucagon responses induced by arginine (by 60%) and Carbamoylcholine chloride (HY-B1208) (by 50%)[1].
Xenin-8 acetate is able to antagonize the inhibition of glucagon release caused by elevated glucose concentrations[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
Molecular Weight 1046.27 (free base)
-
Formula C51H79N15O9·xC2H4O2
-
SMILES
O=C(N1[C@@H](CCC1)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N2[C@@H](CCC2)C(N[C@@H](CC3=CNC4=CC=CC=C34)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC5=CNC=N5)N.CC(O)=O.[x]
-
Sequence
His-Pro-Lys-Arg-Pro-Trp-Ile-Leu
-
Sequence Shortening
HPKRPWIL
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Human Islet Cell Culture
The method of preserving islets in vitro, with purified reduced immunogenicity. The steps are islet isolation, islet cell purification, in vitro determination of islet function and islet cell culture.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)